-
1Academic Journal
Συγγραφείς: T. R. Gvindzhiliya, I. M. Kuzmina, E. V. Klychnikova, E. V. Tazina, A. A. Kochetova, N. A. Muradyan, A. S. Bogdanova, Т. Р. Гвинджилия, И. М. Кузьмина, Е. В. Клычникова, Е. В. Тазина, А. А. Кочетова, Н. А. Мурадян, А. С. Богданова
Πηγή: Transplantologiya. The Russian Journal of Transplantation; Том 16, № 3 (2024); 328-336 ; Трансплантология; Том 16, № 3 (2024); 328-336 ; 2542-0909 ; 2074-0506
Θεματικοί όροι: гемостаз, antiplatelet therapy, glycoprotein IIb/IIIa platelet receptor inhibitors, hemostasis, антиагрегантная терапия, ингибиторы гликопротеиновых IIb/IIIa рецепторов тромбоцитов
Περιγραφή αρχείου: application/pdf
Relation: https://www.jtransplantologiya.ru/jour/article/view/914/883; https://www.jtransplantologiya.ru/jour/article/view/914/890; Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Acute coronary syndromes. Lancet. 2022;399(10332):1347–1358. PMID: 35367005 https://doi.org/10.1016/S0140-6736(21)02391-6; Sharma R, Kumar P, Prashanth SP, Belagali Y. Dual Antiplatelet therapy in coronary artery disease. Cardiol Ther. 2020;9(2):349–361. PMID: 32804330 https://doi.org/10.1007/S40119-020-00197-0; Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999–3054. PMID: 21873419 https://doi.org/10.1093/eurheartj/ehr236; Ускач Т.М., Терещенко А.С. Современная антитромбоцитарная терапия при чрескожном коронарном вмешательстве. Как сделать правильный выбор? Рациональная фармакотерапия в кардиологии. 2020;16(6):1017–1023. https://doi.org/10.20996/1819-6446-2020-11-12; Berwanger O, Nicolau JC, Carvalho AC, Jiang L, Goodman S, Nicholls SJ, et al. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with STelevation myocardial infarction: rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. Am Heart J. 2018;202:89–96. PMID: 29908420 https://doi.org/10.1016/j.ahj.2018.02.017; Altersberger VL, Sturzenegger R, Räty S, Hametner C, Scheitz JF, Moulin S, et al. Prior dual antiplatelet therapy and thrombolysis in acute stroke. Ann Neurol. 2020;88(4):857–859. PMID: 32686168 https://doi.org/10.1002/ANA.25850; Попова Л.В., Аксенова М.Б., Хлевчук Т.В. Антиагрегантная терапия в кардиологии. Клиническая медицина. 2016;94(10):729–736. https://doi.org/10.18821/0023-2149-2016-94-10-729-736; Морозова Т.Е., Вартанова О.А. Антиагреганты в лечении ишемической болезни сердца. Русский медицинский журнал РМЖ. 2007;28:2130.; Deng L, Jia HZ, Li MC, Zhu W. Comparison of the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris in long term follow-up. Kaohsiung J Med Sci. 2021;37(11):1010–1015. PMID: 34338425 https://doi.org/10.1002/KJM2.12421; Layne K, Ferro A. Antiplatelet therapy in acute coronary syndrome. Eur Cardiol. 2017;12(1):33–37. PMID: 30416549 https://doi.org/10.15420/ECR.2016:34:2; Yang M, Huo X, Miao Z, Wang Y. Platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban in acute ischemic stroke. Drugs. 2019;79(5):515–529. PMID: 30838514 https://doi.org/10.1007/S40265-019-01078-0; Blanchart K, Heudel T, Ardouin P, Lemaitre A, Briet C, Bignon M, et al. Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coro nary intervention for ST elevation myocardial infarction in patients pre-treated with newer P2Y12 inhibitors. Clin Cardiol. 2021;44(8):1080–1088. PMID: 34114653 https://doi.org/10.1002/CLC.23654; Deng L, Jia HZ, Li MC, Zhu W. Comparison of the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris in long term follow-up. Kaohsiung J Med Sci. 2021;37(11):1010-1015. PMID: 34338425 https://doi.org/10.1002/KJM2.12421; Li F, Wang S, Wang L, Liu F, Meng Z, Liu J. The effects of ticagrelor combined with tirofiban on coagulation function, serum myocardial injury markers, and inflammatory factor levels in patients with acute myocardial infarction after percutaneous coronary intervention. Comput Math Methods Med. 2022;2022:4217270. PMID: 35529262 https://doi.org/10.1155/2022/4217270; Fu X, Hao Q, Jia X, Fan W, Gu X, Wu W, et al. Effect of tirofiban plus clopi dogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Chin Med J (Engl). 2008;121(6):522–527. PMID: 18364139; Jiang Z, Zhang R, Sun M, Liu Q, Wang S, Wang W, et al. Effect of clopidogrel vs ticagrelor on platelet aggregation and inflammation markers after percutaneous coronary intervention for ST-elevation myocardial infarction. Can J Cardiol. 2018;34(12):1606–1612. PMID: 30527148 https://doi.org/10.1016/J.CJCA.2018.08.024; Xie ZJ, Xin SL, Chang C, Zhou H-J, Zhao X-F, Jiao F-H et al. Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome. PLoS One. 2021;16(2):e0246166. PMID: 33529262 https://doi.org/10.1371/journal.pone.0246166; Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. PMID: 19717846 https://doi.org/10.1056/NEJ-MOA0904327; Liu Y, Liu H, Hao Z, Geng G, Chen Q, Han W, et al. Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI). Int J Clin Exp Med. 2015;8(7):11360–11369. PMID: 26379951; https://www.jtransplantologiya.ru/jour/article/view/914